



BJS

The contracting role of graduated compression stockings in prevention of peri-operative venous thromboembolism

Journal:	<i>British Journal of Surgery</i>
Manuscript ID	BJS-0757-Apr-22
Manuscript Type:	Gloves Off
Date Submitted by the Author:	24-Apr-2022
Complete List of Authors:	Shalhoub, Joseph; Imperial College London, Surgery & Cancer;
Keywords:	General Surgery, Vascular Surgery

SCHOLARONE™
Manuscripts

1
2
3 **The contracting role of graduated compression stockings in prevention of**
4
5 **peri-operative venous thromboembolism**
6
7
8
9

10 Joseph Shalhoub MBBS PhD FRCS FEBVS
11
12
13
14
15
16

17 *Correspondence:*
18
19
20

21 Joseph Shalhoub MBBS PhD FRCS FEBVS
22

23 Imperial Vascular Unit
24

25 Imperial College Healthcare NHS Trust
26

27 St Mary's Hospital
28

29 Praed Street
30

31 London W2 1NY, UK
32
33
34
35
36
37

38 *Email:* j.shalhoub@imperial.ac.uk
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There can be no doubt that the prevention of venous thromboembolism (VTE) is a
4 healthcare need and priority ¹. The issue remains in sharp focus in surgery with the
5 implementation of VTE risk assessment, and the use of mechanical and
6 pharmacological thromboprophylaxis. These measures have been further enhanced
7 through education, dissemination and have been reinforced through key clinical
8 guidelines ^{2, 3} and incentivisation ⁴.
9
10
11
12
13
14
15
16
17
18

19 There has been a 15% reduction in hospital-associated (within 90 days of admission)
20 VTE deaths in the UK between 2010 and 2017 ⁵, with concurrent falls in pulmonary
21 embolism-related mortality amongst European countries ⁶. This is likely to be more
22 impressive when considering that improved awareness and imaging are likely to
23 have increased the diagnosis of VTE, resulting in a further reduction in case fatality
24 rate. The factors responsible for this reduction are likely to be multifactorial. The can
25 be attributed to a long list of varied and important factors, including (but not limited
26 to) prehabilitation, systematic VTE risk assessment (including computer-aided ⁷),
27 enhanced recovery with early mobilisation, patient hydration, advanced minimally
28 invasive surgical techniques resulting in a reduction in the systemic inflammatory
29 response (both magnitude and duration), and of course thromboprophylaxis.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Given the number of relevant factors at play, it is challenging to know which are
48 dominant and this also applies when considering mechanical and pharmacological
49 thromboprophylaxis. Much of the evidence underpinning peri-operative
50 thromboprophylaxis, is dated and may not reflect modern surgical practice.
51 Furthermore, these studies were for the most part using mechanical
52 thromboprophylaxis alone or pharmacological thromboprophylaxis alone, with little
53
54
55
56
57
58
59
60

1
2
3 evidence relating to the use of both mechanical and pharmacological strategies ⁸.
4
5 Many were funded by stocking manufacturers ⁹. It was for these and a number of
6
7 other reasons that doubt was cast over the evidence that formed the basis of
8
9 recommendations for mechanical thromboprophylaxis, particularly the use of
10
11 graduated compression stockings (GCS) ^{9, 10}. What should be considered is whether,
12
13 in individuals receiving pharmacological thromboprophylaxis, does GCS *further*
14
15 reduce the VTE risk.
16
17
18
19
20

21
22 The first CLOTS trial randomised 2518 patients admitted to hospital following an
23
24 acute stroke to receive either routine care including thigh-length GCS, or routine care
25
26 with the avoidance of GCS ¹¹. Not only was there no significant reduction in
27
28 symptomatic or asymptomatic deep vein thrombosis (DVT), complications of skin
29
30 breaks, ulcers, blisters and skin necrosis were significantly more common in the
31
32 GCS arm of the trial ¹². A subsequent RCT was performed amongst individuals in
33
34 critical care who were receiving pharmacological thromboprophylaxis to receive
35
36 either additional intermittent pneumatic compression (n=991) or no additional
37
38 intermittent pneumatic compression (n=1012) ¹². In this trial, the addition of
39
40 intermittent pneumatic compression did not result in a lower incidence of proximal
41
42 lower-limb DVT than pharmacological thromboprophylaxis alone ¹². These studies
43
44
45
46
47
48
49 generated further uncertainty around the role of mechanical thromboprophylaxis in
50
51 medical inpatient and critical care settings, respectively.
52
53
54
55

56
57 What does this mean for the surgical patient? In 2007, an RCT of individuals
58
59 undergoing hip surgery was published ¹³. This compared post-operative VTE or
60

1
2
3 sudden death between those randomised to the combination of fondaparinux and
4 compression stockings (n=395, 19 DVT events) or fondaparinux alone (n=400, 22
5 DVT events), and concluded “the addition of graduated compression stockings to
6
7
8 DVT events), and concluded “the addition of graduated compression stockings to
9
10
11 fondaparinux appears to offer no additional benefit over the use of fondaparinux
12
13
14
15 alone”¹³.

16
17
18
19
20
21
22 This trial set the scene for a large UK National Institute for Health Research (NIHR)-
23
24
25 funded Graduated compression stockings as an Adjunct to Pharmacoprophylaxis in
26
27
28 Surgery (GAPS) Trial. GAPS aimed to elucidate the role of GCS in individuals
29
30
31 undergoing elective surgery who were risk assessed as being at moderate or high
32
33
34 risk for VTE and who were receiving prophylactic dose low molecular weight heparin
35
36
37 (LMWH)¹⁴. The primary outcome, imaging-confirmed lower limb DVT with or without
38
39
40 symptoms, or pulmonary embolism with symptoms within 90 days of surgery
41
42
43
44 occurred in 16 of 937 (1.7%) patients in the LMWH alone group compared with 13 of
45
46
47
48
49
50 921 (1.4%) in the LMWH and GCS group. LMWH alone was confirmed to be
51
52
53 statistically non-inferior (non-inferiority margin of 3.5% risk difference) to the
54
55
56
57 combination of LMWH and GCS in this surgical patient group^{15, 16}. Considering this
58
59
60

1
2
3
4 subgroup of elective surgical patients, removing the cost of purchasing and of the
5
6
7 nursing time required to apply GCS, it has been conservatively estimated that more
8
9
10 than £60 million per annum could be liberated from NHS budgets in England alone
11
12
13
14 on a recurring basis ¹⁴. This estimate did not consider the costs of treating the
15
16
17 complications related to GCS such as those that were reported by the CLOTS
18
19
20 investigators ¹¹. There is an appetite for implementation of the results of the GAPS
21
22
23 trial into widespread clinical practice ¹⁷.
24
25
26
27
28
29
30

31 The RCT by Cohen et al ¹³ and GAPS ^{15, 16} support the diminishing role of GCS in
32
33
34 the prevention of peri-operative VTE. GAPS, however, did not include the full
35
36
37 spectrum of peri-operative patients, for example those having non-elective surgery,
38
39
40 those in whom extended pharmacological thromboprophylaxis is indicated beyond
41
42
43 the inpatient stay (including orthopaedic and abdomino-pelvic surgery), and
44
45
46 individuals assessed as being at low risk for VTE and hence will not be prescribed
47
48
49 pharmacological thromboprophylaxis. For the latter two surgical populations,
50
51
52
53
54
55
56 systematic reviews have been completed to explore the role of GCS. In both cases,
57
58
59 the evidence has been reported to be lacking ^{18, 19}. The recently funded NIHR-
60

1
2
3 funded Prevention of vEnous Thromboembolism in low-risk Surgical patients (PETS)
4
5
6
7 RCT aims to cluster randomise 21,472 participants undergoing day case and short
8
9
10 stay elective surgical procedures who have been risk assessed as being low risk for
11
12
13
14 VTE to receive GCS or no thromboprophylaxis ²⁰.
15
16
17
18

19 The American Public Health Association has stated that the “disconnect between
20
21 evidence and execution as it relates to DVT prevention amounts to a public health
22
23 crisis” ²¹. It can be argued that the same consideration should be given to
24
25 implementation and evidence-based practices in allowing limited healthcare
26
27 resources to be allocated in a way that is maximally impactful to positive patient
28
29 outcomes.
30
31
32
33
34

35 **Acknowledgements**

36
37 The investigators and participants of the GAPS and PETS trials.
38
39
40
41
42
43
44

45 **Declaration of interests**

46
47 JS is an investigator for the NIHR Health Technology Assessment-funded GAPS
48
49 (14/140/61) and PETS (NIHR133776) trials. JS is an investigator for other NIHR and
50
51 British Heart Foundation-funded studies, and has provided consultancy to Oxford
52
53 Healthtech Ltd.
54
55
56
57

58 **References**

59
60

1. Shekelle PG, Pronovost PJ, Wachter RM, McDonald KM, Schoelles K, Dy SM, et al. The top patient safety strategies that can be encouraged for adoption now. *Ann Intern Med.* 2013;158:365-8.
2. Excellence NifHaC. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. 2018.
3. Schunemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv.* 2018;2:3198-3225.
4. Department of Health NE. Using the Commissioning for Quality and Innovation (CQUIN) payment framework: Guidance on national goals for 2011/12. 2010.
5. Hunt BJ. Preventing hospital associated venous thromboembolism. *Bmj.* 2019;365:l4239.
6. Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, Middeldorp S, et al. Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. *The Lancet Respiratory Medicine.* 2019.
7. Lang KJ, Barker RD, Roberts LN, Yorke R, Bonner L, Patel RK, et al. The value of computerised VTE assessments: findings from retrospective audit of 2474 non-consecutive electronic patient records in a VTE exemplar centre. *Br J Haematol.* 2012;157:31.
8. Mandavia R, Shalhoub J, Head K and Davies AH. The additional benefit of graduated compression stockings to pharmacologic thromboprophylaxis in the

- 1
2
3 prevention of venous thromboembolism in surgical inpatients. *J Vasc Surg: Venous and Lym Dis.* 2015;3:447-455.
- 4
5
6
7
8 9. Whittaker L, Baglin T and Vuylsteke A. Challenging the evidence for
9
10 graduated compression stockings. *Bmj.* 2013;346:f3653.
- 11
12 10. Welfare M. NICE's recommendations for thromboembolism are not evidence
13
14 based. *Bmj.* 2011;343:d6452.
- 15
16
17 11. Dennis M, Sandercock PA, Reid J, Graham C, Murray G, Venables G, et al.
18
19 Effectiveness of thigh-length graduated compression stockings to reduce the
20
21 risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre,
22
23 randomised controlled trial. *Lancet.* 2009;373:1958-65.
- 24
25
26 12. Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS,
27
28 et al. Adjunctive Intermittent Pneumatic Compression for Venous
29
30 Thromboprophylaxis. *N Engl J Med.* 2019;380:1305-1315.
- 31
32
33 13. Cohen AT, Skinner JA, Warwick D and Brenkel I. The use of graduated
34
35 compression stockings in association with fondaparinux in surgery of the hip.
36
37 A multicentre, multinational, randomised, open-label, parallel-group
38
39 comparative study. *J Bone Joint Surg Br.* 2007;89:887-92.
- 40
41
42 14. Shalhoub J, Norrie J, Baker C, Bradbury AW, Dhillon K, Everington T, et al.
43
44 Graduated Compression Stockings as an Adjunct to Low Dose Low Molecular
45
46 Weight Heparin in Venous Thromboembolism Prevention in Surgery: A
47
48 Multicentre Randomised Controlled Trial. *European Journal of Vascular and*
49
50 *Endovascular Surgery.* 2017;53:880-885.
- 51
52
53 15. Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, et al.
54
55 Graduated compression stockings as adjuvant to pharmaco-
- 56
57
58
59
60

- 1
2
3 thromboprophylaxis in elective surgical patients (GAPS study): randomised
4 controlled trial. *Bmj*. 2020.
5
6
7
8 16. Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, et al.
9
10 Compression stockings in addition to low-molecular-weight heparin to prevent
11 venous thromboembolism in surgical inpatients requiring
12 pharmacoprophylaxis: the GAPS non-inferiority RCT. *Health Technol Assess*.
13 2020;24:1-80.
14
15
16
17
18
19 17. Lawton R, Shalhoub J and Davies AH. Implementation of the Graduated
20 compression as an Adjunct to Pharmaco-thromboprophylaxis in Surgery
21 (GAPS) trial results across the UK. *Phlebology*. 2022;In Press.
22
23
24
25
26 18. Milinis K, Shalhoub J, Coupland AP, Saliccioli JD, Thapar A and Davies AH.
27 The effectiveness of graduated compression stockings for prevention of
28 venous thromboembolism in orthopedic and abdominal surgery patients
29 requiring extended pharmacologic thromboprophylaxis. *J Vasc Surg Venous*
30 *Lymphat Disord*. 2018;6:766-777 e2.
31
32
33
34
35
36
37 19. Machin M, Younan HC, Smith S, Salim S, Davies AH and Shalhoub J.
38 Systematic review on the benefit of graduated compression stockings in the
39 prevention of venous thromboembolism in low-risk surgical patients.
40 *Phlebology*. 2021;36:184-193.
41
42
43
44
45
46
47 20. Examining the benefit of graduated compression stockings in the Prevention
48 of vEnous Thromboembolism in low-risk Surgical patients: a multicentre
49 cluster randomised controlled trial (PETS Trial).
50
51
52
53
54 21. Association APH. Deep-vein thrombosis: advancing awareness to protect
55 patient lives. White Paper. Public Health Leadership Conference on Deep-
56 Vein Thrombosis. Washington, DC; February 26, 2003. 2003.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FOR REVIEW ONLY